In conclusion, the data here presented indicates that the increased ADA1 to ADA2 ratio in MS CSF and plasma may translate to an unfavorable phenotype that triggers ADA1-mediated pro-inflammatory mechanisms and decreases the ADA2-dependent neuroprotective and growth-promoting effects. The gene discussed is ADA2; the disease is myeloid sarcoma.